Mapping the fitness of Mycobacterium tuberculosis strains: a complex picture

References

1. Billington O. J., McHugh T. D., Gillespie S. H. 1999; Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis . Antimicrob Agents Chemother 43:1866–1869
   [Google Scholar]
2. Böttger E. C., Springer B., Pletschette M., Sander P. 1998; Fitness of antibiotic-resistant microorganisms and compensatory mutations. Nat Med 4:1343–1344 [CrossRef]
   [Google Scholar]
3. Davies A. P., Billington O. J., Bannister B. A., Weir W. R., McHugh T. D., Gillespie S. H. 2000; Comparison of fitness of two isolates of Mycobacterium tuberculosis , one of which had developed multi-drug resistance during the course of treatment. J Infect 41:184–187 [CrossRef]
   [Google Scholar]
4. Gagneux S., Long C. D., Small P. M., Van T., Schoolnik G. K., Bohannan B. J. M. 2006; The competitive cost of antibiotic resistance in Mycobacterium tuberculosis . Science 312:1944–1946 [CrossRef]
   [Google Scholar]
5. Gillespie S. H., Billington O. J., Breathnach A., McHugh T. D. 2002; Multiple drug-resistant Mycobacterium tuberculosis : evidence for changing fitness following passage through human hosts. Microb Drug Resist 8:273–279 [CrossRef]
   [Google Scholar]
6. Jenkins C., Claxton A. P., Shorten R. J., McHugh T. D., Gillespie S. H. 2005; Rifampicin resistance in tuberculosis outbreak, London, England. Emerg Infect Dis 11:931–934
   [Google Scholar]
7. O'Sullivan D. M., McHugh T. D., Gillespie S. H. 2005; Analysis of rpoB and pncA mutations in the published literature: an insight into the role of oxidative stress in Mycobacterium tuberculosis evolution?. J Antimicrob Chemother 55:674–679 [CrossRef]
   [Google Scholar]
8. Pope C. F., Gillespie S. H., Pratten J. R., McHugh T. D. 2008; Fluoroquinolone-resistant mutants of Burkholderia cepacia . Antimicrob Agents Chemother 52:1201–1203 [CrossRef]
   [Google Scholar]
9. Pym A. S., Saint-Joanis B., Cole S. T. 2002; Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70:4955–4960 [CrossRef]
   [Google Scholar]
10. Ramaswamy S., Musser J. M. 1998; Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis : 1998 update. Tuber Lung Dis 79:3–29 [CrossRef]
    [Google Scholar]
11. Sreevatsan S., Pan X., Stockbauer K. E., Connell N. D., Kreiswirth B. N., Whittam T. S., Musser J. M. 1997; Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci U S A 94:9869–9874 [CrossRef]
    [Google Scholar]
12. Telenti A., Imboden P., Marchesi F., Matter L., Schopfer K., Bodmer T., Lowrie D., Colston M. J., Cole S. 1993; Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis . Lancet 341:647–651 [CrossRef]
    [Google Scholar]
13. Telenti A., Honore N., Bernasconi C., March J., Ortega A., Heym B., Takiff H. E., Cole S. T. 1997; Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis : a blind study at reference laboratory level. J Clin Microbiol 35:719–723
    [Google Scholar]
14. Toungoussova O. S., Caugant D. A., Sandven P., Mariandyshev A. O., Bjune G. 2004; Impact of drug resistance on fitness of Mycobacterium tuberculosis strains of the W-Beijing genotype. FEMS Immunol Med Microbiol 42:281–290 [CrossRef]
    [Google Scholar]
15. Van Soolingen D., De Haas P. E. W., Van Doorn R., Kuijper E., Rinder H., Borgdorff M. W. 2000; Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in The Netherlands. J Infect Dis 182:1788–1790 [CrossRef]
    [Google Scholar]
16. Youmans G. P., Youmans A. S. 1949; A method for the determination of the rate of growth of tubercle bacilli by the use of small inocula. J Bacteriol 58:247–255
    [Google Scholar]